These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30828978)

  • 1. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).
    Falco M; Pende D; Munari E; Vacca P; Mingari MC; Moretta L
    HLA; 2019 Apr; 93(4):185-194. PubMed ID: 30828978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.
    Pende D; Falco M; Vitale M; Cantoni C; Vitale C; Munari E; Bertaina A; Moretta F; Del Zotto G; Pietra G; Mingari MC; Locatelli F; Moretta L
    Front Immunol; 2019; 10():1179. PubMed ID: 31231370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
    Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
    Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
    Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
    J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
    Moretta L; Locatelli F; Pende D; Marcenaro E; Mingari MC; Moretta A
    Blood; 2011 Jan; 117(3):764-71. PubMed ID: 20889923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias.
    Moretta A; Pende D; Locatelli F; Moretta L
    Clin Exp Immunol; 2009 Sep; 157(3):325-31. PubMed ID: 19664139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.
    Locatelli F; Pende D; Falco M; Della Chiesa M; Moretta A; Moretta L
    Trends Immunol; 2018 Jul; 39(7):577-590. PubMed ID: 29793748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
    Mavers M; Bertaina A
    J Immunol Res; 2018; 2018():1586905. PubMed ID: 29850617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
    Moretta A; Locatelli F; Moretta L
    Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
    Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
    Norell H; Moretta A; Silva-Santos B; Moretta L
    J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
    Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
    J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell receptors and their ligands in leukemia.
    Verheyden S; Demanet C
    Leukemia; 2008 Feb; 22(2):249-57. PubMed ID: 18046448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of natural killer cell killer immunoglobulin-like receptor-mismatch in transplant outcomes.
    Stringaris K; Barrett AJ
    Curr Opin Hematol; 2017 Nov; 24(6):489-495. PubMed ID: 28817402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactive natural killer cells in targeting high-risk leukaemias.
    Moretta L; Locatelli F; Moretta A
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii39-43. PubMed ID: 19022812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Aversa F; Martelli MF; Velardi A
    Curr Opin Oncol; 2007 Mar; 19(2):142-7. PubMed ID: 17272987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors.
    Baltner K; Kübler A; Pal M; Balvociute M; Mezger M; Handgretinger R; André MC
    Int Immunol; 2017 Nov; 29(9):423-429. PubMed ID: 29099970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.